1,604 results match your criteria Clinical breast cancer[Journal]


A Reappraisal of the Comparative Effectiveness of Lumpectomy Versus Mastectomy on Breast Cancer Survival: A Propensity Score-Matched Update From the National Cancer Data Base (NCDB).

Clin Breast Cancer 2019 Feb 21. Epub 2019 Feb 21.

Gundersen Health System, La Crosse, WI.

Background: Recent observational studies are concerning because they document rising mastectomy rates coinciding with more than a dozen reports that lumpectomy has better overall survival (OS) than mastectomy. Our aim was to determine if there were differences in OS of matched breast cancer patients undergoing lumpectomy versus mastectomy in the National Cancer Database (NCDB).

Patients And Methods: A retrospective cohort of patients with stage I-III breast cancer in the NCDB (2004-2013) was identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.02.006DOI Listing
February 2019

Prophylactic Versus Therapeutic Mastectomy: A Contemporary Analysis of the ACS-NSQIP Database.

Clin Breast Cancer 2019 Jan 31. Epub 2019 Jan 31.

Division of Surgical Oncology, Department of Surgery, University of Massachusetts, Worcester, MA. Electronic address:

Introduction: The objective of the study was to evaluate the morbidity, mortality, and postoperative outcomes associated with simple or subcutaneous mastectomy in the management of prophylactic versus therapeutic resection. In this study we aimed to assess if simple or subcutaneous mastectomy for prophylaxis affects perioperative outcomes compared with resection performed for biopsy proven malignancy.

Materials And Methods: The American College of Surgeons National Surgical Quality Improvement Program database was queried for subjects who underwent simple or subcutaneous mastectomy between 2007 and 2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.008DOI Listing
January 2019

Patterns of Care and Efficacy of Chemotherapy and Radiotherapy in Skin-Involved Breast Cancers of All Sizes.

Clin Breast Cancer 2019 Feb 16. Epub 2019 Feb 16.

Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address:

Background: The management of small skin-involved (SI) invasive breast cancers is controversial because although they are considered unresectable, their prognosis is far better than their stage III classification. This study was undertaken to determine how SI lesions are treated in the United States and to discern the benefit of systemic therapy.

Patients And Methods: Data of patients diagnosed with stage I-III breast cancer in the National Cancer Data Base between 2004 and 2011 were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.02.003DOI Listing
February 2019

Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor-Positive/Human Epidermal Receptor 2-Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs.

Clin Breast Cancer 2019 Feb 16. Epub 2019 Feb 16.

Department of Oncology, Mater Salutis Hospital, Legnago, Italy.

Purpose: To assess the pharmacologic costs of CDK4/6 inhibitors (palbociclib and ribociclib) in hormone receptor-positive (HR)/human epidermal receptor 2-negative (HER2) advanced or metastatic breast cancer (BC). Pivotal phase 3 randomized controlled trials (RCTs) were considered.

Discussion: Two phase 3 RCTs including 1334 patients were considered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.02.004DOI Listing
February 2019

Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.

Clin Breast Cancer 2019 Feb 6. Epub 2019 Feb 6.

Pharmaceutical Care Research Group, School of Pharmacy, University College Cork, Cork, Ireland. Electronic address:

Background: Two large acute Irish University teaching hospitals changed the manner in which they treated human epidermal growth factor receptor (HER)2-positive breast cancer patients by implementing the administration of trastuzumab via the subcutaneous (SC) route into their clinical practice. The study objective is to compare the trastuzumab SC and trastuzuamb intravenous (IV) treatment pathways in both hospitals and assess which route is more cost-effective and time saving in relation to active health care professional (HCP) time.

Materials And Methods: A prospective observational study in the form of cost minimization analysis constituted the study design. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.011DOI Listing
February 2019

Factors Determining Anthracycline Use in Hormone Receptor Positive, Early-Stage Breast Cancer.

Clin Breast Cancer 2019 Feb 7. Epub 2019 Feb 7.

Genesys Research Office, Ascension Genesys, Grand Blanc, MI. Electronic address:

Background: Anthracyclines are associated with significant toxicities whereas nonanthracyclines have proven to be better tolerated. A 21-gene assay allows clinicians to predict who will not benefit from adjuvant chemotherapy and avoid systemic toxicities. Physicians are using the recurrence score to guide chemotherapy selection, despite the lack of evidence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.012DOI Listing
February 2019

Intensive Imaging Surveillance of Survivors of Breast Cancer May Increase Risk of Radiation-induced Malignancy.

Clin Breast Cancer 2019 Jan 23. Epub 2019 Jan 23.

Medical Unit, Translational Research In Oncology (TRIO), Montevideo, Uruguay.

Background: Current clinical guidelines recommend mammography as the only imaging method for surveillance in asymptomatic survivors of early breast cancer (EBC). However, non-recommended tests are commonly used. We estimated the imaging radiation-induced malignancies (IRIM) risks in survivors of EBC undergoing different imaging surveillance models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.003DOI Listing
January 2019
1 Read

A Genetic Variant of rs145204276 in the Promoter Region of Long Noncoding RNA GAS5 Is Associated With a Reduced Risk of Breast Cancer.

Clin Breast Cancer 2018 Nov 14. Epub 2018 Nov 14.

Department of Breast Surgery, the Third Affiliated Hospital of Kunming Medical University, Kunming Yunnan, P.R. China. Electronic address:

Introduction: Growth arrest-specific 5 (GAS5), downregulated in breast cancer (BC), functions as a tumor suppressor by affecting tumor growth and cell apoptosis in vivo and in vitro. This study was designed to determine whether an insertion (ins)/deletion (del) polymorphism (rs145204276 AGGCA/-) in the promoter region of GAS5 was a susceptibility gene to the occurrence of BC.

Patients And Methods: A hospital-based case-control study was conducted and the GAS5 rs145204276 genotype was analyzed in 575 sporadic BC patients and 602 controls to test the association between the polymorphism and BC risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.11.006DOI Listing
November 2018

Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.

Clin Breast Cancer 2019 Feb 7. Epub 2019 Feb 7.

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address:

Background: Fulvestrant 500 mg and exemestane are widely used agents in first-line therapy for metastatic breast cancer (MBC) of estrogen receptor (ER)-positive (ER) postmenopausal MBC after failure of adjuvant nonsteroidal aromatase inhibitor (NSAI) treatment. Although fulvestrant 250 mg had similar efficacy compared with exemestane (Evaluation of Faslodex versus Exemestane Clinical Trial study) and fulvestrant 500 mg was superior to fulvestrant 250 mg (Comparison of FASLODEX In Recurrent or Metastatic Breast Cancer study), no direct comparison between fulvestrant 500 mg and exemestane has been conducted. The aim of this study was to compare the efficacy and safety of fulvestrant 500 mg and exemestane in daily practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.015DOI Listing
February 2019
1 Read
2.107 Impact Factor

ER/HER2 Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2 Breast Cancer.

Clin Breast Cancer 2019 Feb 14. Epub 2019 Feb 14.

Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA. Electronic address:

Background: Human epidermal growth factor receptor 2-positive (HER2) breast cancer is generally treated with HER2-targeted therapy combined with chemotherapy. Patients with HER2 and estrogen receptor-positive (ER) cancer are additionally treated with long-term hormone therapy. This study examined the metastatic pattern and prognosis of both ER/HER2 and ER-/HER2 breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.02.001DOI Listing
February 2019
1 Read
2.107 Impact Factor

Screening Mammography Findings in Women With Chronic Kidney Disease on a Renal Transplant Waiting List.

Clin Breast Cancer 2019 Jan 31. Epub 2019 Jan 31.

Department of Radiology, Health Sciences University, Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey.

Background: The incidence of breast cancer has been reported to be increased in people with chronic kidney disease (CKD). Thus, breast cancer screening is stated to be mandatory. However, it is as yet unclear what age group or what type of breast structure indicate a need for mammography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.009DOI Listing
January 2019
1 Read

Vitamin D Receptor in Breast Cancer Tissues and Its Relation to Estrogen Receptor Alpha (ER-α) Gene Expression and Serum 25-hydroxyvitamin D Levels in Egyptian Breast Cancer Patients: A Case-control Study.

Clin Breast Cancer 2019 Jan 6. Epub 2019 Jan 6.

Department of Applied Medical Chemistry, Medical Research Institute, University of Alexandria, Alexandria, Egypt.

Introduction: This study aimed to explore the role of vitamin D receptor (VDR) in breast cancer tissues and its relation to serum 25-hydroxyvitamin D [25(OH)D] levels and estrogen receptor alpha (ER-α) gene expression in patients with breast cancer.

Patients And Methods: Cancerous and normal breast tissues from 40 women with breast cancer were analyzed for quantification of VDR levels and ER-α gene expression. The serum levels of 25(OH)D were measured in patients with breast cancer and controls by radioimmunoassay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.019DOI Listing
January 2019

Obesity Does Not Influence Management of Advanced Breast Cancer in the Elderly.

Clin Breast Cancer 2019 Jan 12. Epub 2019 Jan 12.

Division of Surgical Oncology, Department of Surgery, Rush University Medical Center, Chicago, IL.

Background: Obesity is becoming increasingly common in the elderly population, and it adds to the complexity of treatment decisions in this population. We aimed to investigate whether body mass index (BMI) affects care in this subset of patients.

Patients And Methods: We performed a retrospective chart review on 118 patients over the age of 70 years diagnosed with breast cancer and pathologically proven axillary disease over an 8-year period at an urban academic hospital and compared BMI to treatment received, clinical stage, and hormone receptor status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.020DOI Listing
January 2019

Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer.

Clin Breast Cancer 2019 Feb 6. Epub 2019 Feb 6.

Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA. Electronic address:

Background: Of women diagnosed with metastatic breast cancer (MBC), 20% to 30% survive ≥5 years. We evaluated data from a large breast cancer program to identify features associated with MBC survival.

Patients And Methods: Women diagnosed with MBC in or after 1999 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.014DOI Listing
February 2019
1 Read

Breast Cancer in Women Aged 80 Years or Older: An Analysis of Treatment Patterns and Disease Outcomes.

Clin Breast Cancer 2019 Jan 31. Epub 2019 Jan 31.

Department of Surgical Oncology, Medical College of Wisconsin, Milwaukee, WI. Electronic address:

No clear standard treatment guidelines exist for older women with breast cancer. In this study we aimed to examine the practice patterns and treatment outcomes of women ≥80 years old with invasive breast cancer. A retrospective chart review at a single academic institution was performed of 124 women diagnosed with stage I to III invasive breast cancer aged ≥80 years between 2005 and 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.007DOI Listing
January 2019
1 Read

The Results of Surveillance Imaging After Breast Conservation Surgery and Partial Breast Reconstruction With Chest Wall Perforator Flaps; A Qualitative Analysis Compared With Standard Breast-Conserving Surgery for Breast Cancer.

Clin Breast Cancer 2019 Jan 31. Epub 2019 Jan 31.

Department of Breast Surgery, Oxford University Hospitals NHS Trust, Oxford, United Kingdom. Electronic address:

Introduction: Partial breast reconstruction (PBR) using chest wall perforator flaps (CWPF) allows for excision of tumors in the outer quadrant of the breast in women with small to moderate non-ptotic breasts resulting in a good aesthetic outcome. There are limited data available in the literature regarding long-term follow-up and the effect of CWPF on subsequent surveillance mammographic interpretation and recall rates. A retrospective audit with qualitative analysis of initial mammograms was performed to assess this. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.010DOI Listing
January 2019

Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer.

Clin Breast Cancer 2019 Jan 29. Epub 2019 Jan 29.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Background: Although younger age is a negative prognostic factor for patients with early stage breast cancer, data regarding the outcomes of young patients with stage IV disease are limited. We evaluated differences in overall survival (OS) according to age and disease subtype among patients with stage IV breast cancer.

Patients And Methods: Using Surveillance, Epidemiology, and End Results (SEER) data, we identified 6,302 patients aged < 60 years with de novo stage IV breast cancer between 2010 and 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.005DOI Listing
January 2019

Prognostic Significance of Obesity and Diabetes Mellitus in Women With Brain Metastases From Breast Cancer Should Be Revisited.

Authors:
Kadri Altundag

Clin Breast Cancer 2019 Jan 23. Epub 2019 Jan 23.

MKA Breast Cancer Clinic, Tepe Prime, Ankara, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.004DOI Listing
January 2019
2 Reads

Significance of Serum Survivin and -31G/C Gene Polymorphism in the Early Diagnosis of Breast Cancer in Egypt.

Clin Breast Cancer 2019 Jan 6. Epub 2019 Jan 6.

Department of Biochemistry, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA), October, Egypt. Electronic address:

Background: Breast cancer is one of the most relevant malignancies among women. Molecular abnormalities in promotor region of survivin gene may account for overexpression of survivin and increased breast cancer risk. This study aimed to explore the potential association between survivin promotor gene -31G/C single nucleotide polymorphism (rs9904341) and its serum level alteration on one hand, and the risk of breast cancer in Egyptian patients on the other hand. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.002DOI Listing
January 2019

Role of Overweight, Obesity, and Comorbidities in the Prognosis of Patients With Breast Cancer With Brain Metastases.

Clin Breast Cancer 2019 Jan 7. Epub 2019 Jan 7.

Epidemiology Unit, Instituto Nacional de Cancerología, México City, México.

Introduction: Breast cancer (BC) is the most common cancer in women, and the incidence of brain metastasis (BM) from BC ranges from 20% to 30%, with a median survival of 10 to 15 months. Previous reports have shown that the presence of obesity or diabetes negatively impacts survival. The present study investigates the association between obesity or diabetes mellitus (DM) and overall survival of patients with BC with BM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.018DOI Listing
January 2019

Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.

Clin Breast Cancer 2019 Jan 3. Epub 2019 Jan 3.

Department of Medicine and Carbone Cancer Center, University of Wisconsin, Madison, WI. Electronic address:

Background: Increased signaling through growth factor receptor pathways, including HER2, plays a role in resistance to endocrine therapy (ET) in patients with hormone receptor (HR)-positive metastatic breast cancer (MBC). Inhibition of mechanistic target of rapamycin improves outcomes when used in addition to ET in patients with HR-positive MBC, who previously received ET. We hypothesized that the additional use of trastuzumab (T) or everolimus (E) could restore sensitivity to ET in patients with endocrine-resistant, HR-positive, HER2-negative MBC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.017DOI Listing
January 2019
2 Reads

Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.

Clin Breast Cancer 2018 Dec 14. Epub 2018 Dec 14.

Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address:

Introduction: Angiogenesis and epidermal growth factor receptor signaling are potential therapeutic targets in triple negative breast cancer (TNBC). We hypothesized that targeting these critical pathways would prolong progression-free survival with first-line therapy for metastatic TNBC.

Patients And Methods: We conducted a phase II trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, for patients with metastatic TNBC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.008DOI Listing
December 2018
2 Reads

Soy Foods Might Weaken the Sensitivity of Tamoxifen in Premenopausal Patients With Lumina A Subtype of Breast Cancer.

Clin Breast Cancer 2018 Dec 12. Epub 2018 Dec 12.

Medical Science Laboratory, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, People's Republic of China. Electronic address:

Background: Based on estrogen active substances, many women consume soy foods in the belief that it could prevent breast cancer (BC). Women with different molecular subtypes would be likely to have diverse reactions to soy foods, especially those with the estrogen-receptor-positive (ER) subtype. The aim of the current study is to identify the differentially expressed genes (DEGs) on soy foods in premenopausal patients with Lumina A subtype of BC (LABC) after soy food treatment, and to further investigate the critical molecule change. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.003DOI Listing
December 2018
9 Reads

Ultrasound-Guided Vacuum-Assisted Biopsy in Small Breast: A Cost-Saving Solution.

Clin Breast Cancer 2018 Dec 7. Epub 2018 Dec 7.

UOC Radiologia, UOS di Senologia Interventistica, Policlinico Tor Vergata: Fondazione PTV, Università di Roma "Tor Vergata", Roma, Italy.

Background: The study aimed to evaluate the feasibility and reliability of ultrasound-guided vacuum-assisted breast biopsy (US-VABB) for sampling of microcalcifications indicative of cancer when stereotactic vacuum-assisted breast biopsy cannot be performed because of reasons such as thin breast tissue, insufficient thickness at compression, and microcalcification situated close to the chest wall or in breast tissue of the axillary tail.

Patients And Methods: The study population was selected from among 187 patients with microcalcifications detected on mammogram. The findings were classified using the American College of Radiology criteria as Breast Imaging Reporting and Data System 3, 4, or 5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.002DOI Listing
December 2018
5 Reads

Comparison of Radioactive Seed Localized Excision and Wire Localized Excision of Breast Lesions: A Community Hospital's Experience.

Clin Breast Cancer 2019 Jan 6. Epub 2019 Jan 6.

Department of Surgery, North York Hospital, Toronto, Ontario, Canada. Electronic address:

Background: Most data comparing wire localized excision (WLE) and radioactive seed localized excision (RSLE) derive from academic institutions with limited data from community hospitals. This study aimed to compare positive margin rates between WLE and RSLE and to determine if there were any differences in specimen volume and operation time.

Patients And Methods: A retrospective cohort study was conducted on patients who underwent WLE or RSLE at a Canadian community hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.001DOI Listing
January 2019
1 Read

A Better Pathway? Building Consensus and Engaging Providers with Feedback to Improve and Standardize Cancer Care.

Clin Breast Cancer 2018 Dec 21. Epub 2018 Dec 21.

QURE Healthcare, San Francisco, CA; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA; Department of Health Policy and Management, University of California, Los Angeles, CA. Electronic address:

Introduction: Unwanted clinical variation is common across the United States health care system and is particularly vexing in oncology owing to the complexity, morbidity, and high cost of the disease. Efforts to standardize care including guidelines and continuing medical education have had only limited impact. Disease-specific oncology clinical pathways hold the promise of reducing variation but have been hampered by a lack of ownership and accountability among oncology providers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.010DOI Listing
December 2018
2 Reads

A Prospective Cohort Study on the Impact of Reflexology in Patients With Breast Cancer Using the MYCaW Scale.

Clin Breast Cancer 2018 Dec 19. Epub 2018 Dec 19.

The Breast Unit, Princess Alexandra Hospital, Harlow, United Kingdom.

Introduction: Breast cancer treatment and recovery remain physically and psychologically challenging for patients. Reflexology has been studied as a complementary therapy to help relieve patients of the physical and psychological stresses involved with breast cancer. As a result of recent positive evidence, we studied its effects quantitatively from 2015 to 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.007DOI Listing
December 2018

Breast Reconstruction Actualized in Nipple-sparing Mastectomy and Direct-to-implant, Prepectoral Polyurethane Positioning: Early Experience and Preliminary Results.

Clin Breast Cancer 2018 Dec 27. Epub 2018 Dec 27.

Department of Plastic and Reconstructive Surgery, Instituti Fisioterapici Ospitalieri, Regina Elena National Cancer Institute, Rome, Italy.

Background: Implant-based breast reconstruction after nipple-sparing mastectomy has been the most common breast reconstruction procedure performed, for both breast cancer treatment and prophylactically. Subpectoral implant placement with partial detachment of the pectoralis major muscle has been the procedure of choice for staged reconstruction and direct-to-implantation. Prepectoral implant placement has recently increased in popularity among plastic surgeons owing to the high rates of animation deformity, loss of muscle function, and chronic pain observed with submuscular implant placement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.015DOI Listing
December 2018

Corrigendum.

Authors:

Clin Breast Cancer 2019 Feb;19(1):87-88

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.016DOI Listing
February 2019

Examining Associations of Racial Residential Segregation With Patient Knowledge of Breast Cancer and Treatment Receipt.

Clin Breast Cancer 2018 Dec 8. Epub 2018 Dec 8.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Electronic address:

Background: The effect of racial residential segregation on breast cancer treatment disparities is unclear. We examined whether racial segregation is associated with adjuvant treatment receipt and patient knowledge of disease.

Patients And Methods: We surveyed a population-based sample of women in Northern California with stage I to III breast cancer diagnosed in 2010 to 2011 (participation rate = 68. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.001DOI Listing
December 2018
2 Reads

8-Hydroxy-2'-deoxyguanosine as a Discriminatory Biomarker for Early Detection of Breast Cancer.

Clin Breast Cancer 2018 Dec 21. Epub 2018 Dec 21.

Department of Otolaryngology, Head and Neck Surgery, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.

Background: Breast cancer (BC) is one of the most prevalent and reported cancers among Saudi women. Detection of BC in the early invasive stage (stages I, II) has an advantage in treating patients over detection in the late invasive stage (stages III, IV). Tumor markers are used to aid in diagnosis, treatment monitoring, and recurrence detection of malignant tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.013DOI Listing
December 2018
1 Read

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.

Clin Breast Cancer 2018 Dec 20. Epub 2018 Dec 20.

Medica Scientia Innovation Research (MedSIR), Barcelona, Spain; Hospital Arnau de Vilanova, Valencia, Spain. Electronic address:

Background: Eribulin has efficacy in patients with progression after ≥ 1 chemotherapeutic regimen for metastatic breast cancer (MBC). A short disease-free interval (DFI) and previous use of taxanes in the neoadjuvant or adjuvant setting have been associated with worse outcomes for patients receiving first-line chemotherapy for HER2-negative MBC. The aim of the present trial was to evaluate the efficacy and safety of eribulin as first-line therapy for patients with HER2-negative MBC with these poor prognostic factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.012DOI Listing
December 2018
2 Reads

Implementation of a Multidisciplinary Model of Care for Women With Metastatic Breast Cancer: Challenges and Lessons Learned.

Clin Breast Cancer 2018 Dec 21. Epub 2018 Dec 21.

Department of Nursing, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia; Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.

Introduction: The present study examined the feasibility and effects of integrating a multidisciplinary team (MDT) model of care for women with metastatic breast cancer (MBC) into a large Australian cancer center. The challenges encountered and lessons learned are described.

Patients And Methods: In the present prospective, longitudinal, mixed-methods implementation study, the MDT model included face-to-face consultations with a breast care nurse and social worker, followed by a MDT case discussion and face-to-face delivery of a personalized management plan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.014DOI Listing
December 2018
1 Read

Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.

Clin Breast Cancer 2018 Dec 20. Epub 2018 Dec 20.

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA.

Background: Despite the availability of several human epidermal growth factor receptor 2 (HER2)-directed treatments, many HER2-positive (HER2) breast cancers eventually progress because of primary or acquired resistance.

Patients And Methods: A 2-part, open-label, multicenter phase I/II study was conducted to determine the recommended dose of neratinib when administered with trastuzumab (part I), and to assess the antitumor activity of this combination in women with locally advanced or metastatic HER2 breast cancer previously treated with at least 1 prior trastuzumab-based regimen (part II). Patients received oral neratinib (160 or 240 mg/d) once daily plus intravenous trastuzumab 4 mg/kg (loading dose) then 2 mg/kg weekly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.011DOI Listing
December 2018
2 Reads

Testosterone and Breast Cancer in Transmen: Case Reports, Review of the Literature, and Clinical Observation.

Clin Breast Cancer 2018 Dec 20. Epub 2018 Dec 20.

Department of Plastic and Reconstructive Microsurgery, Careggi University Hospital, Florence, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.006DOI Listing
December 2018
1 Read

Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles.

Clin Breast Cancer 2018 Dec 12. Epub 2018 Dec 12.

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; Oncology and Haemato-Oncology Department, University of Milan, Milan, Italy. Electronic address:

Background: Single-agent gemcitabine is a moderately effective compound in metastatic breast cancer (mBC) treatment. Carboplatin is frequently used in addition to gemcitabine to improve tumor responses, but with an unclear effect on survival outcomes. In this study we evaluated the antitumor efficacy and safety profiles of gemcitabine and carboplatin-gemcitabine in mBC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.004DOI Listing
December 2018
5 Reads

Impact of Baseline Cardiovascular Comorbidity on Outcomes in Women With Breast Cancer: A Real-world, Population-based Study.

Clin Breast Cancer 2018 Dec 12. Epub 2018 Dec 12.

Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada. Electronic address:

Introduction: The aim of this study was to characterize treatment trends and outcomes of women who have preexisting cardiovascular disease (CVD) prior to the diagnosis of breast cancer.

Patients And Methods: This represented a retrospective, population-based cohort study that analyzed pooled data from the provincial cancer registry, physician billing claims, hospital discharge abstracts, ambulatory care, and the 2011 census in a large Canadian province. Multivariable logistic regression was performed to identify the associations of CVD with breast cancer treatment and outcomes. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15268209183050
Publisher Site
http://dx.doi.org/10.1016/j.clbc.2018.12.005DOI Listing
December 2018
7 Reads
2.107 Impact Factor

The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China.

Clin Breast Cancer 2018 Dec 19. Epub 2018 Dec 19.

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address:

Introduction: UGT1A4 is a major enzyme responsible for the glucuronidation of tamoxifen (TAM) and its metabolites. Genetic variations in the UGT1A4 gene could have a significant impact on the clinical efficacy of TAM. This study was performed to validate the association between UGT1A4 polymorphisms and the clinical outcomes for patients with breast cancer who received adjuvant TAM. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15268209183053
Publisher Site
http://dx.doi.org/10.1016/j.clbc.2018.12.009DOI Listing
December 2018
6 Reads

21-Gene Recurrence Score Testing in HER2-positive Patients.

Clin Breast Cancer 2018 Nov 27. Epub 2018 Nov 27.

Department of Surgery, University of Minnesota Medical School, Minneapolis, MN. Electronic address:

Introduction: The 21-gene recurrence score (RS) has been extensively studied and validated in patients with estrogen receptor-positive (ER), human epidermal growth factor 2 (HER2)-negative breast cancer; however, RS testing is not routinely performed in patients with HER2-positive (HER2) disease. We sought to determine patterns of RS testing, to characterize RS distributions, and to determine the impact of RS results on clinical decision-making for patients with ER, HER2 breast cancer.

Materials And Methods: Using the Surveillance and Epidemiology End Results program database, we identified women with ER, HER2 breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.11.011DOI Listing
November 2018
1 Read

Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade.

Clin Breast Cancer 2018 Nov 26. Epub 2018 Nov 26.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Background: The aim of this study was to determine if, in inflammatory breast cancer (IBC), baseline metabolic activity (maximum standardized uptake value [SUVmax]) of primary tumor and involved regional lymph nodes (IRLN) are prognostic markers of response after neoadjuvant systemic therapy (NAS).

Patients And Methods: Baseline 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography scans were retrospectively reviewed among 61 women with IBC who received NAS, had mastectomy, and had available pathology reports. Primary tumor and IRLN SUVmax were compared between patients with a pathologic complete response (pCR) versus those with residual disease after NAS. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15268209183050
Publisher Site
http://dx.doi.org/10.1016/j.clbc.2018.11.010DOI Listing
November 2018
6 Reads

A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study.

Clin Breast Cancer 2018 Nov 24. Epub 2018 Nov 24.

Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano, IRCCS, Aviano, Italy. Electronic address:

Introduction: Approximately 50% of locally advanced or metastatic breast cancer (MBC) patients treated with first-line exemestane do not show objective response and currently there are no reliable biomarkers to predict the outcome of patients using this therapy. The constitutive genetic background might be responsible for differences in the outcome of exemestane-treated patients. We designed a prospective study to investigate the role of germ line polymorphisms as biomarkers of survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.11.009DOI Listing
November 2018
3 Reads
2.107 Impact Factor

Meta-analysis of the Correlation Between Schizophrenia and Breast Cancer.

Clin Breast Cancer 2019 Feb 3;19(1):e172-e185. Epub 2018 Nov 3.

Department of Obstetrics and Gynecology, Hangzhou First People's Hospital, Hangzhou, China.

Purpose: To determine the correlation between schizophrenia and breast cancer (BC).

Methods: We searched relevant articles indexed in the PubMed, Embase, and Cochrane Library databases; managed the data in Endnote X7 software; evaluated literature quality by Newcastle-Ottawa quality evaluation criteria; designed tables; and extracted relevant data. The main outcome measure was BC incidence. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15268209183009
Publisher Site
http://dx.doi.org/10.1016/j.clbc.2018.10.012DOI Listing
February 2019
7 Reads

Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.

Clin Breast Cancer 2018 Nov 5. Epub 2018 Nov 5.

Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece; Aristotle University of Thessaloniki, Thessaloniki, Greece.

Background: We examined tumor genotype characteristics of human epidermal growth factor receptor 2 (HER2)-positive relapsed (R-) and de novo (dn-) metastatic breast cancer (MBC) in trastuzumab-treated patients who were previously not exposed to this agent.

Materials And Methods: We analyzed genotypes obtained upon deep sequencing from 113 HER2-positive primary tumors from 69 patients with R-MBC and 44 patients with dn-MBC.

Results: Mutations were observed in 90 (79. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.10.014DOI Listing
November 2018
2 Reads

Interdisciplinary Management of Transgender Individuals at Risk for Breast Cancer: Case Reports and Review of the Literature.

Clin Breast Cancer 2019 Feb 14;19(1):e12-e19. Epub 2018 Nov 14.

Department of Surgical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.11.007DOI Listing
February 2019
3 Reads

Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy: A Propensity Score Analysis and Predictors of Care for Patients With Brain Metastases From Breast Cancer.

Clin Breast Cancer 2018 Nov 12. Epub 2018 Nov 12.

Department of Radiation Oncology, Baylor College of Medicine, Houston, TX. Electronic address:

Background: Metastases to the brain occur in 10%-16% of patients with breast cancer, with incidence reportedly increasing. Historically, brain metastases (BM) have been treated with whole-brain radiation therapy (WBRT), but stereotactic radiosurgery (SRS) is an increasingly favored treatment option. In this study we used a population-level database to compare patterns of care and survival between WBRT and SRS for BM from breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.11.001DOI Listing
November 2018
3 Reads

Corrigendum.

Authors:

Clin Breast Cancer 2018 Dec;18(6):511

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.10.006DOI Listing
December 2018
1 Read

Beliefs About Medication and Uptake of Preventive Therapy in Women at Increased Risk of Breast Cancer: Results From a Multicenter Prospective Study.

Clin Breast Cancer 2019 Feb 3;19(1):e116-e126. Epub 2018 Dec 3.

Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom. Electronic address:

Introduction: Uptake of preventive therapies for breast cancer is low. We examined whether women at increased risk of breast cancer can be categorized into groups with similar medication beliefs, and whether belief group membership was prospectively associated with uptake of preventive therapy.

Patients And Methods: Women (n = 732) attending an appointment to discuss breast cancer risk were approached; 408 (55. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.10.008DOI Listing
February 2019
4 Reads

Dietary Habits and Physical Activity are Associated With the Risk of Breast Cancer Among Young Iranian Women: A Case-control Study on 1010 Premenopausal Women.

Clin Breast Cancer 2019 Feb 2;19(1):e127-e134. Epub 2018 Nov 2.

Bahar Center for Education, Research and Treatment, Shahroud University of Medical Sciences, Shahroud, Iran. Electronic address:

Background: Several studies conducted in developed countries introduced diet and physical inactivity as major risk factors for several types of cancers. However, the impact of diet and physical inactivity on the risk of breast cancer (BC) is understudied, and the limited findings are controversial. In addition, no or limited knowledge is available from the developing world. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15268209183062
Publisher Site
http://dx.doi.org/10.1016/j.clbc.2018.10.011DOI Listing
February 2019
77 Reads
2.107 Impact Factor

A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology.

Clin Breast Cancer 2018 Oct 16. Epub 2018 Oct 16.

City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA.

Introduction: Phase II clinical trials including geriatric assessment (GA) measures are critical for improving the evidence base for older adults with cancer. We assessed the efficacy and tolerability of nab-paclitaxel in older adults with metastatic breast cancer (MBC).

Patients And Methods: Patients aged ≥ 65 years with MBC and ≤ 1 previous line of chemotherapy received 100 mg of nab-paclitaxel on days 1, 8, and 15 of a 28-day cycle. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15268209183032
Publisher Site
http://dx.doi.org/10.1016/j.clbc.2018.10.002DOI Listing
October 2018
12 Reads

Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study.

Clin Breast Cancer 2019 Feb 1;19(1):e101-e115. Epub 2018 Nov 1.

Department of Endocrine and Breast Surgery, First Affiliated Hospital of Chongqing Medical University, Chongqing, China, Fudan University, Shanghai, China. Electronic address:

Background: The role of histology subtype on the prognosis of T1-2 breast cancer patients receiving breast-conserving surgery (BCS) is not clear.

Methods: The Surveillance, Epidemiology, and End Results (SEER) Program was used to compare overall survival, second primary cancer-free survival (CFS), and local recurrence risk (LR) for patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC), both receiving BCS.

Results: The study enrolled 196,688 patients with T1-2 disease receiving BCS, including 12,906 with ILC and 183,782 with IDC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.10.010DOI Listing
February 2019
1 Read